Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Hepatitis C 1Hepatitis B 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Temozolomide 3Gemcitabine 3Etoposide 3pembrolizumab 2Rituximab 2Lomustine 2Haloperidol 2Dexamethasone 2Cyclosporine 2vocimagene amiretrorepvec 1trofosfamide 1tinostamustine 1selinexor 1ruxolitinib 1regorafenib 1peginterferon alfa-2b 1osimertinib 1menatetrenone 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1glumetinib 1fludarabine 1etoposide phosphate 1eculizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carbon-11 acetate 1blinatumomab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recurrence × menatetrenone × Clear all
NCT00165633 2008-12-09

A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

Eisai Inc.

Phase 2/3 Terminated
540 enrolled
Gastrointestinal

Carcinoma, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡